Arlene O. Siefker-Radtke, MD

Vadim Koshkin, MD

GU Oncology Now

<p>Arlene O. Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, and Vadim Koshkin, MD, University of California, San Francisco, detail the phase 2 NORSE study design, results, and implications for treating patients with metastatic urothelial carcinoma and FGFR alterations.<p><a href="https://guoncologynow.com/category/asco-2023" target="_blank" rel="noopener">View more ASCO 2023 videos</a>.</p></p>


Drs. Siefker-Radtke, Koshkin on the NORSE Study for Metastatic Urothelial Carcinoma

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

Drs. Siefker-Radtke and Koshkin detail the phase 2 NORSE study design, results, and implications for treating patients with mUC and FGFR alterations.

Drs. Siefker-Radtke, Koshkin on the NORSE Study for mUC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe